Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma
Clinical trial NCT00938223 · COMPLETED
Trial details
- NCT number
- NCT00938223
- Sponsor
- Craig L Slingluff, Jr
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2000-08-01
- Primary completion
- 2003-11-01
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.